Study of T prolymphocytic leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This is an observational study for adults diagnosed with T prolymphocytic leukemia. It aims to learn more about the disease and your care over time, which may help improve treatment planning in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have been diagnosed with T prolymphocytic leukemia
- You can and will sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at people with peripheral T-cell lymphoma, a type of blood cancer. It will use genetic testing to understand different subtypes of the cancer and how they affect patients' outcomes.
This trial is testing a new approach to treat T-cell cancers (leukemia and lymphoma). It may be an option for adults with these cancers who are otherwise in reasonably good health.
This study collects information from people diagnosed with chronic lymphatic leukemia. It may help doctors better understand the disease, track patient needs, and improve future care.
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
This trial tests whether adding targeted drugs to standard chemotherapy works better for adults newly diagnosed with T-ALL. If you have not had any prior treatment for leukemia, this study might be an option.
This study uses advanced tests (genetics and other 'omics' methods) to better understand your leukemia and find a treatment that targets its specific features. It may help if standard treatments haven't worked or stopped working.
Hear when a new Prolymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.